cabotegravir PrEP
Selected indexed studies
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (N Engl J Med, 2021) [PMID:34379922]
- Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention? (HIV Med, 2023) [PMID:36468218]
- HIV Pre-Exposure Prophylaxis. (Infect Dis Clin North Am, 2024) [PMID:38871567]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) pubmed
- Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention? (2023) pubmed
- HIV Pre-Exposure Prophylaxis. (2024) pubmed
- Optimising oral PrEP while awaiting long-acting cabotegravir. (2023) pubmed
- Cabotegravir, a new option for PrEP. (2020) pubmed
- Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. (2023) pubmed
- Long-acting cabotegravir PrEP: a time for cautious optimism. (2023) pubmed
- Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection. (2024) pubmed
- Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. (2024) pubmed
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis. (2023) pubmed